Holcomb; Ryan Erik

Patent Applications and Registrations

Patent applications and USPTO patent grants for Holcomb; Ryan Erik.The latest application filed is for "stable anti-osmr antibody formulation".

Company Profile

5.10.12

Holcomb; Ryan Erik - Fort Collins CO
Holcomb; Ryan Erik - Johnstown CO

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency Grant 11,364,288 - Ruddy , et al. June 21, 2	2022-06-21
Stable Anti-OSMR Antibody Formulation App 20220062414 - Manning; Mark Cornell ; et al.	2022-03-03
High concentration formulations of adalimumab Grant 11,229,702 - Manning , et al. January 25, 2	2022-01-25
Stable anti-OSMR antibody formulation Grant 11,141,479 - Manning , et al. October 12, 2	2021-10-12
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20200261556 - Ruddy; Stephen ; et al.	2020-08-20
Stable Anti-OSMR Antibody Formulation App 20200061188 - Manning; Mark Cornell ; et al.	2020-02-27
Stable anti-OSMR antibody formulation Grant 10,493,149 - Manning , et al. De	2019-12-03
Stable anti-OSMR antibody formulation Grant 10,391,170 - Manning , et al. A	2019-08-27
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20190160158 - Ruddy; Stephen ; et al.	2019-05-30
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20190160157 - Ruddy; Stephen ; et al.	2019-05-30
Stable Anti-osmr Antibody Formulation App 20190054169 - Manning; Mark Cornell ; et al.	2019-02-21
C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency Grant 10,201,595 - Ruddy , et al. Feb	2019-02-12
Stable Anti-osmr Antibody Formulation App 20180333489 - Manning; Mark Cornell ; et al.	2018-11-22
C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency Grant 10,130,690 - Ruddy , et al. November 20, 2	2018-11-20
C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency Grant 10,105,423 - Ruddy , et al. October 23, 2	2018-10-23
C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency Grant 10,080,788 - Ruddy , et al. September 25, 2	2018-09-25
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20180153972 - Ruddy; Stephen ; et al.	2018-06-07
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20180110843 - Ruddy; Stephen ; et al.	2018-04-26
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20180110844 - Ruddy; Stephen ; et al.	2018-04-26
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20180085441 - Ruddy; Stephen ; et al.	2018-03-29
C1-inh Compositions And Methods For The Prevention And Treatment Of Disorders Associated With C1 Esterase Inhibitor Deficiency App 20170224788 - Ruddy; Stephen ; et al.	2017-08-10
C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency Grant 9,616,111 - Ruddy , et al. April 11, 2	2017-04-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.